Houlihan Lokey general counsel sells $71,700 in stock

HLI reported Q3 FY2026 adjusted EPS of $1.94, beating the $1.88 consensus by $0.06 and revenue of $717.0M versus $696.65M (≈$20.35M beat). General Counsel Christopher M. Crain sold 500 Class A shares on April 1 at $143.40 for $71,700 and converted 500 Class B shares into Class A; HLI shares trade at $141.32, near a 52-week low of $134.41 after a 29% decline over six months. The company filed a prospectus supplement for potential resale of up to 32,421 Class A shares; InvestingPro flags HLI as undervalued with a Piotroski Score of 9 and 11 consecutive years of dividend increases.

Analysis

Houlihan-style advisory franchises are high operating-leverage businesses where revenue comes in lumpy buckets tied to large transactions; that makes headline volatility more a function of deal timing and perceived overhang than of steady deterioration in underlying margins. Dual-class share mechanics and periodic resale programs can create headline supply shocks that amplify price moves well beyond the economic impact of the actual share count being released.

The main macro sensitivities to monitor are interest-rate trajectories and corporate balance-sheet liquidity: a modest tightening in credit markets can compress transaction activity within 3–9 months and materially lower near-term revenue while leaving long-term franchise economics intact. Governance concentration (voting trusts, founders/insiders holding control) reduces the probability of value-destructive corporate actions but raises the importance of any slow-moving unlocking events as catalysts for re-rating.

Second-order winners from a rebound in deal flow include specialized boutiques and valuation advisory boutiques that compete on niche sectors, while exchange operators and index/ETF fee pools decouple — so the stock should be read more as a M&A-cycle lever than an exchange- or listings-play. The market often overshoots both directions: a short-term supply overhang can create an entry window that compresses realized risk if you mitigate headline dilution exposure and time horizon to the next 2–4 reported quarters of deal activity.

Key Decisions for Investors

• Buy HLI shares with a 9–18 month horizon sized 2–3% of portfolio and hedge headline-dilution risk by purchasing a protective put ~15–20% OTM with 9–12 month tenor; this caps downside while preserving upside if deal activity normalizes (target 30–60% upside if M&A rebounds).
• If prefer limited-cost exposure, initiate a 12-month call spread (buy-to-open one lower strike call / sell-to-open a higher strike call 25–40% apart) to express a cyclical recovery view while limiting capital at risk — set breakeven ~15% above current and target 2.5x payoff at expiration.
• Sell a cash-secured put 2–3 months out at ~20–25% OTM to collect premium and establish a cheaper long basis; treat assignment as an intention to own with an effective yield boost, and limit position sizing to 1–2% notional to avoid large drawdowns if deal markets freeze.
• Pair trade (event/isolate risk): go long HLI and short NDAQ on equal-dollar basis to isolate M&A advisory beta from exchange/listing beta, holding 6–12 months. Use an 8–10% stop-loss on the pair to control idiosyncratic execution risk — expected payoff if M&A activity improves is asymmetric toward HLI.
• Catalyst monitoring: set alerts for quarterly advisory revenues and any filings that materially increase free-float (shelf or conversion notices). If two consecutive quarters show contracting deal count or if a large unlocking event is announced, reduce exposure by 50% within 30 days.